From Antisense RNA to RNA Modification: Therapeutic Potential of RNA-Based Technologies

Area of Science:

• Molecular Biology
• Genetics
• RNA Therapeutics

Background:

• Therapeutic oligonucleotides target RNA to correct genetic mutations via mechanisms like mRNA degradation and splicing modulation.
• Approved antisense oligonucleotides (ASOs) include gapmers, splice-modulating oligos, and siRNAs, primarily enabling gene downregulation or splicing correction.

Purpose of the Study:

• To review current FDA-approved antisense oligonucleotide mechanisms of action and enabling technologies.
• To explore novel RNA modification-based therapeutic modalities for precise genetic repair.

Main Methods:

• Review of FDA-approved oligonucleotide therapeutics and their mechanisms.
• Discussion of emerging epitranscriptomic RNA modification techniques.

Main Results:

• Established antisense oligonucleotide mechanisms (RNase H-dependent degradation, splice modulation, siRNA interference) are effective for genetic disorders.
• Novel RNA modification strategies like ADAR-mediated editing, pseudouridylation, and 2'-O-methylation show therapeutic promise.

Conclusions:

• Oligonucleotide therapeutics have advanced genetic disorder treatment.
• Epitranscriptomic modifications represent a promising frontier for highly specific, single-nucleotide RNA repair, offering an alternative to DNA editing.